BioGaia AB (BIOG B)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:BioGaia AB (BIOG B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012298
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
BioGaia AB (BioGaia) is a biopharmaceutical company, which develops, markets and sells probiotic products. The company sells its probiotic food supplements and oral health products in various dosage forms including drops, lozenges, tablets, chewable tablets, oral rehydration salts (ORS), straws and infant formulas. BioGaia’s products are based on various strains of Lactobacillus reuteri, its patented lactic acid bacterium. Its products improve the digestive and oral health of children and adults, and controls digestive problems such as colic, regurgitation, diarrhea and constipation. The company’ sells its products through distributors in the Americas, Europe and Asia-Pacific. BioGaia is headquartered in Stockholm, Sweden.

BioGaia AB (BIOG B) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
BioGaia AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
BioGaia AB, Medical Devices Deals, 2011 to YTD 2017 10
BioGaia AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
BioGaia AB, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
BioGaia Extends Licensing Agreement With Nestle For Lactobacillus Reuteri 13
BioGaia Enters into Agreement with Laboratorios Silanes 14
BioGaia Enters Into Distribution Agreement With Ache Labs 15
BioGaia Enters Into Distribution Agreement With Dong Sung For Baby Drops And Tablets 16
BioGaia Enters Into Distribution Agreement With Dexcel Pharma For Oral Health Products 17
BioGaia Enters Into Distribution Agreement With Ferozsons Labs For Probiotic Drops And Tablets 18
BioGaia Enters Into Distribution Agreement With United Labs 19
BioGaia Enters Into Co-Marketing Agreement With Laboratoires Pharmaceutiques GALENICA 20
Licensing Agreements 21
Infant Bacterial Therapeutics Enters into Licensing Agreement with BioGaia 21
BioGaia Enters Into Licensing Agreement With Nestle For Lactobacillus Reuteri 22
BioGaia Enters Into Licensing Agreement With Nestle Mexico For ProTectis 23
BioGaia Enters Into Licensing Agreement With Nestle 24
Equity Offering 25
Infant Bacterial Therapeutics Raises USD18 Million in Private Placement of Shares 25
Infant Bacterial Therapeutics to Raise up to USD52.4 Million in Rights Offering of Shares 27
Infant Bacterial Therapeutics Raises USD12 Million in Rights Offering of Shares 29
BioGaia to Invest USD4.1 Million in Infant Bacterial Therapeutics 30
BioGaia Raises Additional USD0.52 Million from Infant Bacterial Therapeutics 31
Acquisition 32
BioGaia Acquires Additional 9% Stake in MetaboGen for USD0.43 Million 32
BioGaia Acquires Additional 12% Stake in MetaboGen for USD0.5 Million 33
BioGaia Acquires 15% Stake in MetaboGen for USD0.5 Million 34
BioGaia To Acquire Remaining 50% Stake In TwoPac For US$4.6 Million 35
BioGaia AB – Key Competitors 36
BioGaia AB – Key Employees 37
BioGaia AB – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 40
Strategy And Business Planning 40
Jun 21, 2017: BioGaia sets up subsidiary for the development of probiotic drugs 40
Financial Announcements 41
Aug 18, 2017: BioGaia Interim report 1 January – 30 June 2017 41
May 03, 2017: BioGaia – Interim management statement 1 January – 31 March 2017 42
Feb 10, 2017: BioGaia – Year-end report 2016 43
Oct 25, 2016: BioGaia: Interim management statement 1 January – 30 September 2016 44
Aug 17, 2016: BioGaia – Interim report 1 January – 30 June 2016 45
May 10, 2016: BioGaia: Interim management statement 1 January – 31 March 2016 46
Apr 27, 2016: BioGaia: IBT’s Results for the First Quarter of 2016 47
Feb 12, 2016: BioGaia – Year-end report 2015 48
Government and Public Interest 49
Aug 08, 2016: BioGaia: BioGaia’s Oral Health Probiotic Reduces Pregnancy Gingivitis 49
Product News 50
May 17, 2016: BioGaia’s Probiotic Effective in Treating Abdominal Pain in Children 50
Other Significant Developments 51
Sep 14, 2016: BioGaia’s probiotics to be launched in Kenya, Nigeria and Ghana 51
Apr 25, 2016: BioGaia’s oral health probiotics to be launched in Hong Kong 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
BioGaia AB, Pharmaceuticals & Healthcare, Key Facts, 2016 2
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
BioGaia AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
BioGaia AB, Deals By Therapy Area, 2011 to YTD 2017 9
BioGaia AB, Medical Devices Deals, 2011 to YTD 2017 10
BioGaia AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
BioGaia Extends Licensing Agreement With Nestle For Lactobacillus Reuteri 13
BioGaia Enters into Agreement with Laboratorios Silanes 14
BioGaia Enters Into Distribution Agreement With Ache Labs 15
BioGaia Enters Into Distribution Agreement With Dong Sung For Baby Drops And Tablets 16
BioGaia Enters Into Distribution Agreement With Dexcel Pharma For Oral Health Products 17
BioGaia Enters Into Distribution Agreement With Ferozsons Labs For Probiotic Drops And Tablets 18
BioGaia Enters Into Distribution Agreement With United Labs 19
BioGaia Enters Into Co-Marketing Agreement With Laboratoires Pharmaceutiques GALENICA 20
Infant Bacterial Therapeutics Enters into Licensing Agreement with BioGaia 21
BioGaia Enters Into Licensing Agreement With Nestle For Lactobacillus Reuteri 22
BioGaia Enters Into Licensing Agreement With Nestle Mexico For ProTectis 23
BioGaia Enters Into Licensing Agreement With Nestle 24
Infant Bacterial Therapeutics Raises USD18 Million in Private Placement of Shares 25
Infant Bacterial Therapeutics to Raise up to USD52.4 Million in Rights Offering of Shares 27
Infant Bacterial Therapeutics Raises USD12 Million in Rights Offering of Shares 29
BioGaia to Invest USD4.1 Million in Infant Bacterial Therapeutics 30
BioGaia Raises Additional USD0.52 Million from Infant Bacterial Therapeutics 31
BioGaia Acquires Additional 9% Stake in MetaboGen for USD0.43 Million 32
BioGaia Acquires Additional 12% Stake in MetaboGen for USD0.5 Million 33
BioGaia Acquires 15% Stake in MetaboGen for USD0.5 Million 34
BioGaia To Acquire Remaining 50% Stake In TwoPac For US$4.6 Million 35
BioGaia AB, Key Competitors 36
BioGaia AB, Key Employees 37
BioGaia AB, Other Locations 38
BioGaia AB, Subsidiaries 38

★海外企業調査レポート[BioGaia AB (BIOG B)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Medherant Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Medherant Ltd (Medherant) is a transdermal drug delivery patch company. The company develops and commercializes novel technologies for delivery of drugs through the skin using expertise in bioadhesives and polymer chemistry to treat pain, Alzheimer's disease, and for smoking cessation, hormo …
  • Douglas Holding AG:戦略・SWOT・企業財務分析
    Douglas Holding AG - Strategy, SWOT and Corporate Finance Report Summary Douglas Holding AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Enbridge Inc (ENB):企業の財務・戦略的SWOT分析
    Enbridge Inc (ENB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Syngenta AG:企業の戦略的SWOT分析
    Syngenta AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Fcmb Group Plc
    Fcmb Group Plc - Strategy, SWOT and Corporate Finance Report Summary Fcmb Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Immunovia AB (IMMNOV):企業の製品パイプライン分析
    Summary Immunovia AB (Immunovia) is a molecular diagnostics company that offers clinical testing for early diagnosis of pancreatic cancer. The company develops IMMray, a technology platform based on antibody microarray analysis, which can be used in the early diagnosis of cancer, predicting disease …
  • Saudi Electricity Co (5110):企業の財務・戦略的SWOT分析
    Saudi Electricity Co (5110) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Bechtel Corp:企業の戦略的SWOT分析
    Bechtel Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Federal Signal Corporation:企業の戦略・SWOT・財務分析
    Federal Signal Corporation - Strategy, SWOT and Corporate Finance Report Summary Federal Signal Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • ImmusanT Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary ImmusanT Inc (ImmusanT) is a clinical stage biotechnology company that discovers, develops and delivers peptide-based immune therapies for the treatment of patients with autoimmune diseases. The company develops its therapeutic vaccines using its epitope-specific immuno-therapy (ESIT) platfo …
  • Time Dotcom Berhad (TIMECOM):企業の財務・戦略的SWOT分析
    Time Dotcom Berhad (TIMECOM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Commercial Bank Of Ceylon Plc:企業の戦略・SWOT・財務分析
    Commercial Bank Of Ceylon Plc - Strategy, SWOT and Corporate Finance Report Summary Commercial Bank Of Ceylon Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • IREN SpA (IRE):電力:M&Aディール及び事業提携情報
    Summary IREN SpA (IREN) is a multi-utility. It generates and sells electricity and thermal energy; sells gas; collects, selects, recovers and disposes urban waste; and provides integrated water services, and public lighting, global services and other services. The company produces power in hydro, th …
  • St. George’s University of London-製薬・医療分野:企業M&A・提携分析
    Summary St. George's University of London (SGUL), a subsidiary of University of London is a medical and healthcare education provider that offers undergraduate and post graduate courses. The university’s undergraduate courses include biomedical science BSc, healthcare practice DipHE and BSc, healthc …
  • Berg LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Berg LLC (Berg) is a biopharmaceutical company that focus on therapeutic discovery using AI-based Interrogative biology platform. The company’s proprietary platform Interrogative Biology, combines patient biology and artificial intelligence-based analytics to understand predictive patterns o …
  • Evogene Ltd (EVGN):企業の財務・戦略的SWOT分析
    Summary Evogene Ltd (Evogene), a subsidiary of Compugen Ltd, is a biotechnology company that offers plant genomic services. The company offers solutions for crop production improvement through breeding. It develops biotechnology and advanced breeding improved traits for crops that feed the world, in …
  • AngioChem Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary AngioChem Inc (AngioChem) is a clinical-stage biotechnology company that discovers and develops new drugs to treat brain related disorders. The company’s products comprise oncology products, peptide antibody conjugates, antibody-drug conjugates, pain products and lysosomal storage diseases p …
  • ERG SpA (ERG):企業の財務・戦略的SWOT分析
    ERG SpA (ERG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Yingli Green Energy Holding Company Limited (YGE):電力:M&Aディール及び事業提携情報
    Summary Yingli Green Energy Holding Company Limited (Yingli Solar) is a solar panel manufacturer. It designs, assembles, sells, and installs solar PV systems. It covers the entire value chain of solar PV industry ranging from designing to manufacturing of multicrystalline polysilicon ingots, wafers, …
  • Regulus Therapeutics Inc (RGLS):医療機器:M&Aディール及び事業提携情報
    Summary Regulus Therapeutics Inc (Regulus Therapeutics) is a biopharmaceutical company that discovers and develops microRNA based therapeutics. The company provides single stranded oligonucleotides, which are chemically synthesized chains of nucleotides that are mirror images of specific target micr …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆